Combination bronchodilator therapy for chronic obstructive pulmonary disease (COPD) is available widely quite through the world except in North America.

Combination bronchodilator therapy for chronic obstructive pulmonary disease (COPD) is available widely quite through the world except in North America. Previous studies have yielded conflicting issues regarding the advantages of combining anticholinergic therapy with sympathomimetic therapy in COPD We report the flows of a 12-week prospective, double-blind, parallel-group evaluation of the use of the following: albuterol, a [beta]-adrenergic agent; ipratropium, an anticholinergic agent; or a combination of the sum of two units administered by metered-dose inhaler to patients with moderately unrelenting stable COPD. Following baseline studies, 534 patients were given common of the three test bronchodilator preparations to be used at dwelling four times daily in addition to oral theophylline and corticosteroids as required. The doses of the latter brace drugs were kept stable. make liables were tested on days 1 29 57 and 85 Analysis of 1- forced expiratory convolution ([FEV.sub.1]) curves on those criterion days indicated that the combination was superior to either single agent alone in peak import in the effect during the first 4 h after dosing, and in the total area in a less degree than the curve of the [FEVsub1] reply The mean peak percent increases in [FEVsub1] above baseline on the four touchstone days were 31 to 33 percent for the combination, 24 to 25 percent for ipratropium, and 24 to 27 percent for albuterol. The differences between the combination and its ingredients were statistically significant on all experiment days. The [AUC.sub.0-4] means for the combination were 21 to 44 percent greater than the ipratropium means and 30 to 46 percent greater than the albuterol means. Similar changes were noted in the forced vital capacity inflects Symptom scores did not change through time and did not differ among the treatment disposes We conclude that the combination of ipratropium and albuterol, when given from metered-dose inhaler to patients with COPD is more effective than either of the sum of two units agents alone. The advantage of the combination is apparent primarily during the first 4 h after administration. The availability of combination therapy by means of metered-dose inhaler should help to improve patient compliance.

Inhaled bronchodilators are widely used for symptomatic relief in chronic obstructive pulmonary disease (COPD) Studies have shown that COPD and asthma can no longer be distinguished forward the basis of reversibility of bronchial obstruction.[1] In fact, Anthonisen et al,[2] measuring rejoinders to isoproterenol over a period of nearly 3 years in a research of 985 patients with COPD for whom asthma was a criterion for exclusion, establish that the patients responded to inhalation of the [beta]-agonist aerosol with an average increase of 15 percent across the initial [FEV.sub.1], corresponding to an increase of approximately 5 percent of their predicted normal [FEVsub1]

In COPD however, [beta]-agonists are surpassed in efficacy through quaternary anticholinergic bronchodilators.[3,4] It has been intimateed by way of explanation that cholinergically mediated airway polished muscle tone may be increased in COPD[5] and/or accounts in large part for the reversible constituent of airway obstruction in COPD or that patients with COPD are les responsive to adrenergic agents because these agents inhibit the flat muscle contraction induced by mediators of the like kind as histamine and the leukotrienes, which play and nothing else a minor role in COPD[6]

To date, seven studies have compared the concomitant use of ipratropium and albuterol, delivered at inhalation aerosol, in patients with COPD with use of each of the individual remedys In five of these trials,[7-11] superior bronchodilation was obtained with the mix with drugs combination. In the remaining couple studies,[12,13] no additive effects of the inferior drug were demonstrable despite the use of higher than approveed doses. All of these trials had serious design limitations. Generally, the sample sizes were too small to attain statistical significance. The studies were inadequately blinded and of short duration, and in many of them the combination was administered as the third criterion drug after treatment with each of the components

A retrospective investigation in 296 patients with partially reversible airflow obstruction showed that in 33 percent of the patients who corresponded inadequately to albuterol alone, bronchodilation was increased when inhalation of this [beta]-agonist was followed by the agency of inhalation of ipratropium.[14]

A fixed combination of a reasonable dose of another [beta]-agonist, fenoterol, and ipratropium in the same metered-dose inhaler (MDI) has been used worldwide, object in North America, for periods ranging up to 10 years. In several controll trials, patients with COPD be agreeable toed to this combination with a greater improvement in lung function than when they were treated with either fenoterol or ipratropium alone.[15-18] A 3-day cogitation in 12 patients with stable COPD compared a combination of standard inhaled doses of ipratropium and metaproterenol with ipratropium alone. This combination was not base to provide any added benefit throughout monotherapy with the anticholinergic agent.[19]

...